total number of show in page
The CentriMag Centrifugal Blood Pump as a Benchmark for In Vitro Testing of Hemocompatibility in Implantable Ventricular Assist Devices

The CentriMag Centrifugal Blood Pump as a Benchmark for In Vitro Testing of Hemocompatibility in Implantable Ventricular Assist Devices

The CentriMag Centrifugal Blood Pump as a Benchmark for In Vitro Testing of Hemocompatibility in Implantable Ventricular Assist Devices Implantable rotary left ventricular assist devices (LVADs) have emerged as mainstream treatment for severely symptomatic heart failure in selected nontransplant eligible patients (1,2). Survival data from INTERMACS suggest that LVAD outcomes now rival transplantation particularly in patients with ischemic cardiomyopathy (3). This has stimulated interest in even smaller devices aimed at improving quality of life and minimizing potentially life- threatening complications. Pump thrombosis and systemic thromboembolism persist as the major limi- tation of this technology and has proven difficult to predict from in vivo testing in sheep or calves (4). Nonetheless, extensive preclinical testing is manda- tory prior to clinical application of any new LVAD (5).

6 Dec 2021
Bridge-to-Decision Therapy With a Continuous-Flow External Ventricular Assist Device in Refractory Cardiogenic Shock of Various Causes

Bridge-to-Decision Therapy With a Continuous-Flow External Ventricular Assist Device in Refractory Cardiogenic Shock of Various Causes

Mortality for refractory cardiogenic shock remains high. In this patient cohort, there have been mixed results in mechanical circulatory support device use as a bridge-to-decision therapy. We evaluated a continuous-flow external ventricular assist device (VAD), CentriMag VAD (Thoratec Corp., Pleasanton, CA), in patients with various causes of refractory cardiogenic shock

6 Dec 2021
Durable Continuous-Flow Mechanical Circulatory Support

Durable Continuous-Flow Mechanical Circulatory Support

Given the increasing shortage of donor organs, implantable mechanical circulatory support (MCS) systems for ventricular assist device (VAD) therapy have emerged as an essential element of treatment [1–24]. These devices are installed permanently in many patients, and fewer are now undergoing heart transplantation (Htx). During waiting periods for donor availability, the VAD system provides additional support as well as improves the physiology of the heart.

6 Dec 2021
Multicentre clinical trial experience with the HeartMate 3

Multicentre clinical trial experience with the HeartMate 3

Lorem ipsum dolor sit amet, sed irure ligula nunc, ornare id aliquet aliquam purus, pulvinar consequat eget ipsum, justo a viverra. Mauris tristique purus morbi magna vivamus, dolor suspendisse phasellus sollicitudin, vel nulla fringilla ut tellus. Ut ut maecenas, laudantium vitae egestas, tenetur vitae dui ac commodo, faucibus odio aliquam ligula proin facilisis penatibus, conubia rutrum dolor eu libero. Ipsum consectetuer. In odio felis semper sodales, laoreet et commodo sit ut, lacus eget eros.

7 Dec 2021
Two-year outcomes with a magnetically levitated cardiac pump in heart failure

Two-year outcomes with a magnetically levitated cardiac pump in heart failure

In an eqrly analysis of this trial. use of a magnetically levited centrifugal continus flow circulatory pump was found to improve clinical outcomes, as compared with a mechanical-bearing axial continuouuus-flow pump, at 6 months in patients with advanced heart failure.

7 Dec 2021
total number of show in page